Geographic Atrophy (GA) Market by Manufacturers, Regions, Type and Application Forecast to 2031

0
590

The global geographic atrophy (GA) market is anticipated to witness steady growth, with a Compound Annual Growth Rate (CAGR) of 7.2% over the forecast period from 2023 to 2030. Geographic atrophy, also known as advanced dry age-related macular degeneration (AMD), is a progressive degenerative eye disease characterized by the gradual loss of retinal cells and central vision. Key factors driving the growth of the GA market include:

Aging Population and Increasing Disease Burden: The aging population, coupled with the rising prevalence of age-related macular degeneration (AMD), is driving market growth and demand for innovative therapies and treatment modalities to address the unmet medical needs of patients with geographic atrophy.

Advancements in Disease Understanding and Biomarker Development: Continuous advancements in disease understanding, biomarker identification, and molecular profiling are driving innovation in GA research and drug development, enabling the identification of novel therapeutic targets and precision medicine approaches for personalized treatment strategies.

Emerging Therapeutic Modalities and Pipeline Candidates: The emergence of novel therapeutic modalities, including complement inhibitors, anti-inflammatory agents, neuroprotective agents, and cell-based therapies, is driving market growth and investment in GA drug development pipelines, offering promising treatment options for patients with geographic atrophy.

Clinical Trials and Regulatory Landscape: The increasing investment in clinical trials, regulatory support, and expedited review pathways for orphan diseases and unmet medical needs are driving market growth and acceleration of GA drug development programs, facilitating faster market access and approval of innovative therapies.

Patient Advocacy and Awareness Initiatives: Patient advocacy groups, disease awareness campaigns, and educational initiatives are driving market growth and raising awareness about geographic atrophy, highlighting the impact of vision loss on patients' quality of life and advocating for early diagnosis, timely intervention, and access to innovative treatments.

Collaborative Research and Industry Partnerships: Collaborative research initiatives, academic-industry partnerships, and consortia efforts are driving market growth and fostering collaboration among key stakeholders, including pharmaceutical companies, academic institutions, government agencies, and patient advocacy organizations, to accelerate GA research and drug development.

MARKET SEGMENT

By Age Group

  • Above 60 Years
  • Above 75 Years

By Diagnosis

  • Fundus Autofluorescence (FAF)
  • Optical Coherence Tomography Angiography (OCT-A)
  • Multifocal Electroretinography (mfERG)

By Therapeutic Agents Clinical Phase

  • Late-stage (Phase III)
  • Phase II
  • Phase I
  • Pre-clinical stage & Discovery candidates

The Key players are AstraZeneca plc, Gyroscope Therapeutics Limited, Hoffmann-La Roche AG, Apellis Pharmaceuticals, Inc., Iveric Bio, Gensight Biologics SA, Stealth BioTherapeutics, Allegro Ophthalmics, LLC, Regenerative Patch Technologies, LLC, Genentech, Inc., Alkeus Pharmaceuticals, Inc., NGM Biopharmaceuticals Inc., Hemera Biosciences LLC, and Other Players.

As the global healthcare community continues to prioritize vision health, age-related diseases, and precision medicine approaches, the geographic atrophy market is expected to witness sustained growth, driven by technological innovation, clinical research advancements, and increasing demand for novel therapies that preserve and restore vision in patients with geographic atrophy.

Other Reports You May Like:

Personalized Medicine Market Growth

Neuroscience Market Growth

Microfluidics Market Growth

Mass Spectrometry Market Growth

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

info@snsinsider.com,

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),

Website: https://www.snsinsider.com

Search
Sponsored
Categories
Read More
News
Explore Apartments Dallas, TX 75240: Modern Living at Its Best
Dallas, Texas, is known to be a very happening place with a very rich culture and a high job rate...
By Fortuna Apartments 2024-09-20 07:27:07 0 301
Health
Retinal Implants Market Detailed Analysis, Technology Trends, Competitive Landscape, Industry Size, Share, Deployment and Future Growth Opportunities till 2032
The retinal implants market is a dynamic arena within the field of medical technology, offering...
By Amol Shinde 2024-04-26 08:33:39 0 667
Home
Tips to pack and have a more organized move
Many people are excited about moving into a new house or apartment and purchasing their new home,...
By Metakomiste Metakomisi 2022-03-04 11:36:49 0 2K
Industry
Empowering Customer Service With Salesforce Help Portal
Call customer support and wait in the queue to get answers! Customers don’t like to wait to...
By CRM Jetty 2024-07-12 12:42:49 0 884
Health
Expert Fertility Doctor in Electronic City, Bangalore: Bringing Hope to Families
For couples or individuals struggling to conceive, the journey towards parenthood can be a...
By Akash Chopra 2023-10-18 09:43:46 0 1K